GPCR-ErbB transactivation pathways and clinical implications

Srikanth Palanisamy, Carolyn Xue, Shun Ishiyama, Sathyamangla Venkata Naga Prasad, Kathleen Gabrielson

Research output: Contribution to journalReview articlepeer-review


Cell surface receptors including the epidermal growth factor receptor (EGFR) family and G-protein coupled receptors (GPCRs) play quintessential roles in physiology, and in diseases, including cardiovascular diseases. While downstream signaling from these individual receptor families has been well studied, the cross-talk between EGF and GPCR receptor families is still incompletely understood. Including members of both receptor families, the number of receptor and ligand combinations for unique interactions is vast, offering a frontier of pharmacologic targets to explore for preventing and treating disease. This molecular cross-talk, called receptor transactivation, is reviewed here with a focus on the cardiovascular system featuring the well-studied GPCR receptors, but also discussing less-studied receptors from both families for a broad understanding of context of expansile interactions, repertoire of cellular signaling, and disease consequences. Attention is given to cell type, level of chronicity, and disease context given that transactivation and comorbidities, including diabetes, hypertension, coronavirus infection, impact cardiovascular disease and health outcomes.

Original languageEnglish (US)
Article number110092
JournalCellular Signalling
StatePublished - Oct 2021


  • Cardiovascular diseases
  • EGFR family signaling
  • GPCR
  • Transactivation

ASJC Scopus subject areas

  • Cell Biology


Dive into the research topics of 'GPCR-ErbB transactivation pathways and clinical implications'. Together they form a unique fingerprint.

Cite this